Abstract:A wave of SARS-CoV-2 infection speedily emerged in Shanghai, China,
since late February 2022. Paxlovid is a therapeutic hybrid of different
compounds and a novel SARS-CoV-2 protease inhibitor by blocking an
enzyme required for viral protein synthesis. It could reduce the risk of
hospitalization or death by 89% as well as being benefit for
immunocompromised and severe COVID-19 patients. Our registry study
indicated that the days of viral elimination and inflammation factors,
such as IL-6, IL-10 and interferon-α… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.